Figure 3From: LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patientsTrend analysis of the levels of LecT-Hepa, FIB-4, and APRI during 48 weeks of IFN treatment. Forty-five patients with CHC who achieved RVR were classified into non-LC (<12 kPa, n = 18), indeterminate (12–18 kPa, n = 14), and LC (≥18 kPa, n = 13) groups according to the degrees of severity of liver fibrosis assessed by FibroScan. Trend analysis of the levels of LecT-Hepa (A), FIB-4 (B), and APRI (C) during the treatment process in these three groups was performed.Back to article page